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Summary
Background.  —  The  beneﬁts  of  vascular  closure  devices  (VCDs)  in  the  prevention  of  vascular
complications  after  femoral  intervention  remain  controversial.
Aim. —  To  evaluate  the  efﬁciency  of  collagen  plug-based  VCDs  in  the  prevention  of  femoralcomplications;
Balloon  aortic
valvuloplasty
access complications  after  balloon  aortic  valvuloplasty.
Methods.  —  We  conducted  a  prospective  analysis  of  consecutive  patients  who  underwent  balloon
aortic valvuloplasty  by  femoral  retrograde  technique  in  our  centre  between  2009  and  2012.
Group 1  included  75  patients  in  whom  femoral  puncture  haemostasis  was  obtained  with  the  use
of an  8F  collagen  plug-based  VCD  (Angio-SealTM;  Saint-Jude  Medical,  Inc.);  group  2  included
Abbreviations: BAV, balloon aortic valvuloplasty; CI, conﬁdence interval; OR, odds ratio; PCI, percutaneous coronary intervention; RR,
elative risk; TAVI, transcatheter aortic valve implantation; VCD, vascular closure device.
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105  patients  who  had  manual  or  mechanical  groin  compression  (FemoStopTM;  RADI  Medical  Sys-
tems, Inc.).  We  did  not  use  heparin  during  the  procedure.  We  collected  data  on  major  in-hospital
adverse  events,  major  bleeding  (Bleeding  Academic  Research  Consortium  classiﬁcation  ≥  3)  and
vascular  access  complications.
Results.  —  We  included  180  patients  with  severe  and  symptomatic  aortic  stenosis.  Indications
for valvuloplasty  were  mainly  bridge  to  transcatheter  aortic  valve  implantation  or  palliative
therapy (72%).  The  groups  were  similar  in  terms  of  median  age,  lower  limb  artery  disease  and
body mass  index.  Vascular  and  bleeding  complications  occurred  in  11.1%  of  patients  and  were
not decreased  with  the  use  of  VCDs  (relative  risk  2.60,  95%  conﬁdence  interval  1.10—3.09;
P =  0.05).  These  ﬁndings  were  consistent  across  all  prespeciﬁed  subgroups.  Duration  of  hospital
stay was  not  reduced  by  VCDs.
Conclusions.  —  Based  on  the  results  of  this  study,  performed  with  small-size  sheaths  and
without heparin,  collagen  plug-based  VCDs  increase  femoral  access  complications  following
aortic valvuloplasty.  Systematic  use  of  VCDs  in  elderly  patients,  with  probable  advanced  limb
atherosclerosis,  is  questionable.
© 2015  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Contexte.  — L’intérêt  des  dispositifs  de  fermeture  vasculaire  pour  prévenir  les  complications
vasculaires  après  intervention  percutanée  fémorale  reste  controversé.  Ceux-ci  ont  par  ailleurs
été évalués  essentiellement  après  angioplastie  coronaire.
Objectif.  — Évaluer  l’efﬁcacité  des  dispositifs  de  fermeture  percutanée  à  base  de  collagène
pour prévenir  les  complications  vasculaires  après  valvuloplastie  aortique  au  ballon.
Méthodes.  — Il  s’agit  d’une  étude  prospective  menée  entre  2009  et  2012,  incluant  180  patients
consécutifs  qui  bénéﬁcient  d’une  valvuloplastie  aortique  au  ballon  par  voie  fémorale  rétrograde
pour sténose  aortique  serrée.  Dans  le  groupe  1  (n  =  75),  un  dispositif  de  fermeture  percutané
de taille  8F  (Angio-SealTM ;  Saint-Jude  Medical,  Inc.)  est  utilisé  au  niveau  de  l’abord  vasculaire
fémoral ;  dans  le  groupe  2  (n  =  105),  une  compression  fémorale  manuelle  ou  mécanique  est
réalisée (FemoStopTM,  RADI  Medical  Systems,  Inc.).  L’héparine  n’est  pas  utilisée  pendant  la
procédure.  Les  complications  intra-hospitalières  majeures,  les  complications  vasculaires  et  les
évènements  hémorragiques  graves  (≥  BARC  classe  3)  sont  évaluées.
Résultats.  —  La  valvuloplastie  aortique  est  faite  essentiellement  en  « pont  » avant  TAVI  ou
en traitement  palliatif  (n  =  130  ;  72  %).  Les  deux  groupes  ont  des  caractéristiques  cliniques
similaires  :  âge  moyen  84  ans,  antécédent  d’artériopathie  périphérique  et  index  de  masse
corporelle.  Des  complications  vasculaires  ou  hémorragiques  sont  observées  parmi  11,1  %  des
patients et  sont  signiﬁcativement  plus  fréquentes  dans  le  groupe  1  (RR  2,60,  95  %  CI  1,10—3,09  ;
p =  0,05).  Ces  résultats  sont  observés  dans  tous  les  sous-groupes  prédéﬁnis.  La  durée  de
l’hospitalisation  n’est  pas  différente  entre  les  2  groupes  (p  =  0,3).
Conclusions.  —  Cette  étude  montre  des  résultats  défavorables  en  termes  de  complications  vas-
culaires et  hémorragiques  des  dispositifs  de  fermeture  percutanée  utilisés  après  valvuloplastie
aortique réalisée  avec  de  petits  désilets  et  sans  héparine.  L’utilisation  systématique  de  ces
dispositifs chez  des  patients  âgés  avec  athérosclérose  fémorale  fréquente  apparaît  discutable.
© 2015  Elsevier  Masson  SAS.  Tous  droits  réservés.
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aIntroduction
A  resurgence  of  balloon  aortic  valvuloplasty  (BAV)  has  taken
place  during  the  past  decade,  alongside  a  rapid  expansion  in
the  population  of  elderly  patients  with  severe  aortic  steno-
sis  and  signiﬁcant  co-morbidities  and  the  development  of
percutaneous  valve  replacement  therapies  [1—5].Whereas  the  complications  of  BAV  have  been  markedly
reduced  by  improvements  in  techniques  and  materials,  the
main  risks  of  the  procedure  remain  (i.e.  complications  at  the
u
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pemoral  entry  site,  with  a  high  risk  of  bleeding,  the  need  for
lood  transfusion  or  vascular  lesions,  which  can  affect  up
o  10%  of  patients)  [2,5—8]. Reducing  vascular  and  bleeding
vents  has  become  an  important  goal  in  interventional  cardi-
logy,  because  they  are  associated  with  mortality,  morbidity
nd  prolonged  hospitalization  [9,10].
Vascular  closure  devices  (VCDs),  which  are  frequently
sed  to  obtain  rapid  femoral  haemostasis  and  patient  deam-
ulation,  are  controversial  with  regard  to  their  ability  to
revent  femoral  vascular  access  complications.  The  use
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f  these  devices  in  the  particular  setting  of  BAV  has  only
een  evaluated  in  small  and  retrospective  series  [11,12].
his  question  is  of  major  concern,  because  BAV  needs
arge  French  size  arterial  puncture  and  is  usually  performed
n  elderly  patients,  who  often  have  advanced  lower  limb
therosclerosis,  which  may  increase  the  risk  of  vascular
omplications.
The  objective  of  this  prospective  study  was  to  compare
CDs  with  manual  or  mechanical  compression  in  terms  of  the
ccurrence  of  femoral  vascular  access  and  bleeding  events.
ethods
atient population
ll  patients  who  were  referred  to  the  Department  of  Car-
iology  at  the  University  Hospital  of  Montpellier,  France  for
AV  between  2008  and  2012  were  included  in  this  prospec-
ive  study.  All  the  patients  had  severe  symptomatic  aortic
tenosis  secondary  to  degenerative  disease,  conﬁrmed  by
ransthoracic  echocardiography  (mean  gradient  >  40  mmHg
nd/or  S  <  1  cm2),  and  were  not  candidates  for  aortic  valve
eplacement.  The  logistic  euroSCORE  (European  System  for
ardiac  Operative  Risk  Evaluation)  was  calculated  for  all
atients  [13].  Patients  with  signiﬁcant  (>  2)  aortic  regurgi-
ation  and  lack  of  femoral  vascular  access  were  excluded.
or  all  patients,  there  was  discussion  of  the  therapeutic
ptions  for  treating  aortic  stenosis,  including  an  assessment
f  the  risks  of  BAV  and  of  surgical  aortic  valve  replace-
ent.  Patients  were  referred  for  BAV  for  palliation  of  heart
ailure  symptoms,  treatment  of  cardiogenic  shock  or  as  a
ridge  to  transcatheter  aortic  valve  implantation  (TAVI),
urgical  aortic  valve  replacement  or  non-cardiac  surgery.
nticoagulation  therapy  with  vitamin  K  antagonists  was
ithdrawn  before  BAV,  and  the  procedure  was  performed
hen  the  international  normalized  ratio  was  <  2.  Platelet
nti-aggregation  therapy  was  continued.
alloon aortic valvuloplasty procedure
he  BAV  procedure  was  performed  by  the  same  operat-
ng  team  of  three  experienced  interventional  cardiologists
ccording  to  the  standard  technique  via  the  retrograde
emoral  approach,  using  8F  or  9F  sheaths.  The  aortic  valve
as  crossed  under  ﬂuoroscopic  guidance  with  a  0.034-inch
traight  guidewire  through  an  Amplatz  catheter  (Boston  Sci-
ntiﬁc,  Marlborough,  MA,  USA).  The  aortic  valve  gradient
as  measured  from  simultaneous  pressure  recordings  from
he  left  ventricle  and  the  descending  aorta  through  the
heath.  An  Amplatz  0.038-inch  StiffTM guidewire  (Boston  Sci-
ntiﬁc)  is  shaped  to  have  a  curved  tip;  it  was  advanced  into
he  left  ventricle  through  the  Amplatz  catheter  and  left  in
lace  while  the  Amplatz  catheter  was  removed  under  ﬂuo-
oscopic  guidance.  BAV  was  performed  by  using  20F,  22F  or
3F  non-compliant  dilatation  balloons  catheters  (TyshakTM;
.  Braun  Interventional  Systems,  Inc.,  Bethlehem,  PA,  USA).
o  stabilize  the  balloon  position  across  the  valve,  the  heart
as  paced  at  a  high  rate  (180—200  beats/min)  through  the
se  of  a  temporary  pacemaker  positioned  in  the  right  ven-
ricle  through  the  femoral  vein.  The  goal  was  to  obtain
 mean  pressure  gradient  <  20  mmHg  or  a  decrease  in  the
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nitial  gradient  of  50%.  If  this  goal  was  not  achieved  and
o  procedural  complications  occurred,  the  procedure  could
e  repeated  using  a  larger  balloon  catheter,  but  without
xceeding  a balloon/ring  ratio  of  >  1.2.
Patients  were  divided  into  two  groups  according  to
emoral  puncture  site  haemostasis  method.  Group  1
onsisted  of  patients  who  had  femoral  closure  with  a  colla-
en  plug-based  VCD  (8F  Angio-SealTM; St.  Jude  Medical,  Inc.,
t.  Paul,  MN,  USA);  group  2  included  those  who  had  manual
ompression  of  the  femoral  puncture  site,  aided  or  not  by
 compression  device  (FemoStopTM; RADI  Medical  Systems,
nc.,  Uppsala,  Sweden).  The  three  interventional  cardiolo-
ists  had  experience  with  the  device,  as  they  had  used  it
or  several  years  for  femoral  intervention,  with  sheath  sizes
etween  6F  and  9F.  The  choice  of  whether  or  not  to  use  a  VCD
uring  the  procedure  was  left  at  the  discretion  of  the  inter-
entional  cardiologist.  In  accordance  with  recent  reports,
e  did  not  use  heparin  during  the  procedure  [14].  We  recom-
ended  that  all  patients  remained  in  an  elongated  position
ntil  the  day  after  the  procedure;  however,  patients  with
evices  without  vascular  complications  could  sit  in  the  bed
fter  2  hours.  A  pressure  bandage  was  applied  in  all  patients
n  the  manual  compression  group,  but  not  in  the  VCD  group
ithout  bleeding  or  vascular  complications.
linical endpoints
linical  events  were  evaluated  during  the  hospital  stay  and
t  1-month  follow-up,  and  were  compared  between  the  two
roups  of  patients.  Our  primary  combined  endpoint  was
valuation  of  severe  vascular  and  bleeding  complications.
evere  vascular  complications  included  femoral  pseudoa-
eurysm  or  arteriovenous  ﬁstulae  requiring  surgery  or
ndovascular  intervention,  acute  limb  ischaemia  and  groin
nfection.  Severe  bleeding  events  were  deﬁned  as  a  score  ≥  3
ccording  to  the  Bleeding  Academic  Research  Consortium
lassiﬁcation  [15].
Our  secondary  endpoint  was  all  adverse  events,  includ-
ng  death,  heart  failure,  signiﬁcant  aortic  regurgitation,
yocardial  infarction  (deﬁned  as  a rise  in  troponin  greater
han  3  times  the  99th  percentile  of  the  upper  reference
imit),  stroke,  mesenteric  ischaemia  or  systemic  embolism.
e  also  evaluated  duration  of  hospital  stay  in  the  two
roups.
tatistical analysis
atient  characteristics  are  presented  using  medians  and
5—75%  interquartile  ranges  or  means  ±  standard  deviations
or  continuous  variables  and  frequencies  and  proportions
or  categorical  variables.  The  two  groups  were  compared
sing  the  Kruskall—Wallis  test  for  continuous  variables  and
he  Chi2 or  Fisher’s  test  for  categorical  variables.  Relative
isks  (RRs)  and  their  95%  conﬁdence  intervals  (CIs)  were  cal-
ulated  between  the  two  groups.  A  multivariable  analysis  of
he  factors  associated  with  severe  complications  was  carried
ut  using  logistic  regression,  using  a backward  selection  of
he  variables.  The  -to-enter  and  -to-exit  were  set  at  0.20
nd  0.15,  respectively.  Odds  ratios  (ORs)  with  95%  CIs  were
alculated.  The  statistical  bilateral  signiﬁcance  threshold
as  set  at  5%.  Statistical  analyses  were  performed  using  SAS
ersion  9.1  (SAS  Institute,  Cary,  NC,  USA).
p
n
5
P
c
A
N
e
(
w
p
m
i
a
t
9
D
I
s
v
i
o
T
t
a
t
r
U
p
V
1
o
f
(
(
c
t
l
a
r
u
t
o
f
(
a
p
a
cVascular  closure  devices  after  aortic  valvuloplasty  
Results
Patient population
Between  2008  and  2012,  180  consecutive  patients  under-
went  BAV  (six  repeat  procedures,  four  second  repeat
procedures),  including  75  patients  (41.7%)  with  femoral  clo-
sure  obtained  with  a  VCD  (group  1)  and  105  patients  (58.3%)
who  had  manual  or  mechanical  compression  of  the  femoral
puncture  site  (group  2).
The  baseline  characteristics  of  the  patients  (Table  1)
were  identical  between  the  two  groups:  same  median
age  (84  years),  prevalence  of  peripheral  vascular  disease
(overall  n  =  47;  26%),  body  mass  index  (mean  27  kg/m2)
and  existence  of  previous  platelet  anti-aggregation  therapy
(overall  n  =  100;  55%).  The  main  indications  for  BAV  were
palliative  procedure  or  bridge  to  TAVI  (n  =  130;  72%);  other
indications  were  bridge  to  surgery  (n  =  35;  19%)  and  cardio-
genic  shock  (n  = 15;  8%).  A  good  haemodynamic  result  with
a  decrease  in  initial  gradient  of  at  least  50%  was  obtained  in
all  patients.
Severe vascular and bleeding complications
The  primary  composite  endpoint  was  achieved  in  20  patients
(11.1%)  overall.  Major  bleeding  was  the  most  common
adverse  event,  occurring  in  16  patients  (8.9%),  whereas
severe  vascular  complications  occurred  in  seven  patients
(3.9%)  (Table  2).  Acute  limb  ischaemia  occurred  in  six
patients  (3.3%)  —  ﬁve  of  whom  belonged  to  the  VCD  group
(P  =  0.08)  —  and  was  related  to  device  obstruction,  according
to  peroperative  data.  We  observed  groin  infection  in  three
patients,  all  of  whom  were  in  group  1  (4%;  P  =  0.07)  and  had
vascular  complications  (pseudoaneurysm).
The  use  of  a  VCD  was  therefore  associated  with  an
increased  risk  of  vascular  and  bleeding  complications  in
general  (RR  2.60,  95%  CI  1.10—3.09;  P  =  0.05);  the  risk  par-
ticularly  concerned  major  bleeding  complications,  which
were  signiﬁcantly  increased  with  VCD  use  (4.7%  vs  14.6%;
P  =  0.02).
Unsuccessful  deployment  of  the  device  occurred  in  ﬁve
patients  in  the  VCD  group  (6.6%),  three  of  whom  had  vas-
cular  complications  (two  pseudoaneurysms  and  one  large
haematoma  requiring  transfusion).
The  majority  of  vascular  complications  occurred  during
the  ﬁrst  day  after  deployment  of  the  device  (80%).
Secondary endpoints
Overall,  seven  (3.9%)  patients  died  during  follow-up:  three
patients  (4.0%)  in  group  1  and  four  patients  (3.8%)  in  group
2  (P  =  0.60).  Death  was  related  to  cardiogenic  shock  caused
by  severe  left  ventricular  dysfunction  in  three  cases,  and
to  annular  rupture  during  the  procedure  in  one  patient.
One  death  was  related  to  severe  pulmonary  infection,  which
occurred  in  a  patient  who  had  acute  limb  ischaemia  (group
1).  One  death  was  related  to  renal  failure  in  a  patient  with
a  large  groin  haematoma  after  failure  of  device  deployment
(group  1).
One  patient  in  group  2  had  an  atrioventricular  block
requiring  pacemaker  implantation.  In  four  patients  (two  in
each  group),  we  observed  mild  aortic  regurgitation  after  the
t
r
i
a253
rocedure.  Duration  of  hospital  stay  was  5  ±  4  days,  with
o  signiﬁcant  difference  between  the  two  groups  (6  ±  2  vs
 ±  3  days;  P  =  0.3).
redictive factors for vascular and bleeding
omplications
ge  (P  =  0.14),  left  ventricular  ejection  fraction  (P  =  0.04),
ew  York  Heart  Association  class  (P  =  0.20),  history  of  periph-
ral  vascular  disease  (P  =  0.20),  body  mass  index  <  25  kg/m2
P  =  0.05)  and  platelet  anti-aggregation  therapy  (P  =  0.5)
ere  not  associated  with  the  primary  outcome.  Among
atients  with  lower  body  mass  index  (<  25  kg/m2),  the  pri-
ary  endpoint  was  achieved  in  20%  in  group  1 (n  =  3)  and
n  22%  in  group  2  (n  =  4)  (P  =  0.5).  After  adjustment  for  the
bove  factors,  the  use  of  a  VCD  remained  associated  with
he  occurrence  of  severe  complications  (adjusted  OR  1.64,
5%  CI  95%  1.20—4.2;  P  =  0.02).
iscussion
n  this  single-centre  prospective  study  including  180  con-
ecutive  patients,  the  use  of  a  VCD  after  balloon  aortic
alvuloplasty  generates  a  higher  risk  of  vascular  and  bleed-
ng  complications  (RR  2.60;  P  =  0.05)  compared  with  manual
r  mechanical  compression  of  the  femoral  puncture  site.
he  risk  of  major  bleeding  was  signiﬁcantly  increased  with
he  use  of  a VCD  (P  =  0.02).  The  trend  towards  increased
cute  limb  ischaemia  (P  =  0.08)  related  to  device  obstruc-
ion  should  also  be  noted.  Duration  of  hospital  stay  was  not
educed  by  the  use  of  a  VCD.
se of vascular closure devices after
ercutaneous femoral interventions
CDs  are  medical  devices  that  were  introduced  in  the  early
990s  in  an  effort  to  reduce  the  time  to  haemostasis,  to
btain  early  ambulation  and  improve  patient  comfort  after
emoral  angiography  or  percutaneous  coronary  intervention
PCI).  Most  VCDs  focus  on  technologies  involving  a  suture
PercloseTM; Abbott  Vascular,  Redwood  City,  CA,  USA)  or  a
ollagen  plug  (Angio-Seal).  The  Angio-Seal  device  is  among
he  most  widely  used  of  the  VCDs  [16].
Currently,  there  is  no  compelling  evidence  that  VCDs
ower  complication  rates  or  have  an  impact  on  major
ccess  site  bleeding.  Clinical  data  mainly  come  from  non-
andomized  post-hoc  subgroup  analyses  based  on  small
nderpowered  studies  or  meta-analyses.  In  all  these  studies,
he  decision  to  use  a  VCD  was  always  left  at  the  discretion
f  the  operator.
In  the  ACUITY  trial  of  11,983  patients  who  underwent
emoral  angiography  or  PCI,  4307  (35.9%)  received  a  VCD
Angio-Seal  in  2971  patients).  In  the  PCI  group,  the  use  of
 VCD  reduced  access  site  bleeding  by  22%  according  to  a
ost-hoc  analysis.  However,  this  trial  only  focused  on  major
ccess  site  bleeding  and  did  not  consider  other  vascular
omplications,  such  as  pseudoaneurysm,  arteriovenous  ﬁs-
ula  or  limb  ischaemia.  Furthermore,  patients  who  did  not
eceive  a  VCD  had  a  higher  rate  of  hypertension  and  renal
nsufﬁciency,  and  more  frequently  had  elevated  biomarkers
nd  anaemia,  which  may  have  increased  the  likelihood  of
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Table  1  Baseline  characteristics  of  patients  who  underwent  balloon  aortic  valvuloplasty  at  Montpellier  University  Hos-
pital,  between  2008  and  2012.
Group  1
(VCD)
(n  =  75)
Group  2  (no
VCD)
(n  = 105)
P
Age  (years) 84  (78—87) 84  (80—89) 0.37
Men  38  (50.6) 46  (43.8) 0.58
Diabetes  21  (28.0)  24  (22.8)  0.55
BMI  (kg/m2)  27  ±  4  25  ±  4  0.60
LVEF  0.92
>  45%  42  (56.0)  58  (55.2)
35—35%  15  (20.0)  17  (16.1)
25—35%  10  (13.3)  15  (14.2)
<  25%  8  (10.6)  15  (14.2)
NYHA  functional  class  0.12
I  or  II  14  (18.6)  21  (20.0)
III  27  (36.0)  40  (38.1)
IV  34  (45.3)  45  (42.8)
Peripheral  vascular  disease  21  (28.0)  26  (24.7)  0.79
Coronary  artery  disease  45  (60.0)  50  (47.6)  0.17
Platelet  anti-aggregation  therapy  48  (64.0)  52  (49.5)  0.55
Creatinine  clearance  <  30  mL/mina 10  (13.3)  12  (11.4)  0.60
Data are median (interquartile range), mean ± standard deviation or number (%); BMI: body mass index; LVEF: left ventricular ejection
fraction; NYHA: New York Heart Association; VCD: vascular closure device.
a By the Modiﬁcation of Diet in Renal Disease equation.
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tntervention  because  of  haemorrhage  in  this  group  [10].  In  a
ost-effectiveness  analysis,  Bos  et  al.  [17]  showed  that  the
se  of  Angio-Seal  did  not  reduce  pseudoaneurysm  and  arteri-
venous  ﬁstulas.  From  the  New  England  Women  PCI  registry,
hmed  et  al.  [18]  reported  a  28%  reduction  in  risk  of  bleed-
ng  with  VCDs,  signiﬁcant  only  in  patients  at  high  risk  of
leeding.  The  results  of  meta-analyses  are  discordant.  The
eta-analysis  of  Nikolsky  et  al.  [19]  involved  a  total  of  30
tudies  concerning  37,066  patients.  The  risk  of  access  site-
elated  complications  was  similar  for  Angio-Seal  compared
ith  mechanical  compression.  The  meta-analysis  of  Vaitkus
t  al.  [20]  included  16  studies  enrolling  5048  patients  after
iagnostic  catheterization  and  PCI.  The  Angio-Seal  device
c
t
e
Table  2  Vascular  and  bleeding  complications  according  to  va
Vascular  complications  and/or  bleeding,  in  general  (n  =  20;  11.
Pseudoaneurysm  and  AV  ﬁstula  (n  =  7;  3.9%)  
Groin  infection  (n  =  3;  1.7%)  
Acute  limb  ischaemia  (n  =  6;  3.3%)  
Dissection  (n  =  4;  2.2%)  
Major  bleeding  (≥  BARC  classiﬁcation  3)  (n  =  16;  8.9%)  
RBC  transfusion  >  1  (n  =  11;  6.1%)  
Retroperitoneal  haematoma  (n  =  1;  0.6%)  
Data are number (%); AV: arteriovenous; BARC: Bleeding Academic R
device.as  associated  with  a  signiﬁcant  reduction  in  risk  (OR  0.51)
nd  Perclose  had  a  neutral  result  (OR  1.0),  whereas  the
asoSealTM device  (Datascope  Corp.,  Montvale,  NJ,  USA)  had
n  increased  risk  of  complications  (OR  1.18).  More  recently,
urm  et  al.  [21], in  an  observational  cohort  study  con-
erning  28,528  angioplasty  procedures  using  VCDs,  showed
hat  the  devices  were  associated  with  reductions  in  vascular
omplications  (OR  0.78,  [95%  CI  0.67—0.90];  P  =  0.001)  and
ransfusions.
VCDs  have  introduced  a  new  set  of  iatrogenic
omplications,  some  of  which  are  virtually  exclusive
o  VCDs,  such  as  infection,  which  is  an  uncommon  but
xtremely  serious  complication,  and  femoral  obstruction  by
scular  closure  device  use.
Group  1  (VCD)(n =  75)  Group  2  (no
VCD)
(n  =  105)
P
1%)  12  (16.0)  8  (7.6)  0.05
5  (6.6)  2  (1.9)  0.13
3  (4.0)  0  0.07
5  (6.6)  1  (0.9)  0.08
2  (2.7)  2  (1.9)  0.86
11  (14.6)  5  (4.7)  0.02
9  (12.0)  2  (1.9)  0.008
1  (1.3)  0  0.42
esearch Consortium; RBC: red blood cell; VCD: vascular closure
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iVascular  closure  devices  after  aortic  valvuloplasty  
the  device,  leading  to  acute  limb  ischaemia  or  retroperi-
toneal  haemorrhage  [21—23].  In  our  study,  we  observed
ﬁve  patients  who  had  acute  limb  ischaemia  related  to
device  obstruction  in  the  VCD  group.  One  of  these  patients
died  as  a  result  of  acute  renal  failure  after  prolonged
hospitalization.
VCD  failure  is  rare,  but  when  the  device  does  fail,  it  is
associated  with  a  signiﬁcant  increase  in  the  risk  of  vascular
complications.  From  a  prospective  registry  of  9823  consecu-
tive  patients  undergoing  cardiac  catheterization,  Bangalore
et  al.  [24]  showed  that  unsuccessful  deployment  or  failure
to  achieve  haemostasis  was  observed  in  3.0%  of  PCI  patients
and  was  associated  with  a  signiﬁcantly  increased  risk  of
any  major  or  minor  vascular  complications  (6.7%  vs  1.4%;
P  <  0.0001).  The  authors  observed  an  increased  risk  of  VCD
failure  with  a  suture-based  device  compared  with  a  collagen
plug-based  device  (P  <  0.001)  [24].
In  our  study,  in  which  only  collagen  plug-based  devices
were  considered,  six  patients  (6.6%)  had  unsuccessful
deployment  of  the  device;  three  of  these  patients  had  vas-
cular  complications,  indicating  the  severity  of  this  event.
The  rate  of  failure  was  higher  than  that  observed  by  Ben
Dor  et  al.,  probably  because  our  study  involved  more  elderly
patients  with  atherosclerotic  arteries.  Furthermore,  the  use
of  larger  sheaths  (8F  and  9F)  than  those  used  for  diagnostic
and  therapeutic  coronary  interventions  (4F  to  6F)  may  have
contributed  to  our  results  [24].
Use of vascular closure devices after  balloon
aortic valvuloplasty
While  BAV  requires  larger  sheaths  than  those  usually  used
after  percutaneous  coronary  intervention,  and  heparin  is
frequently  associated  with  the  procedure,  VCDs  may  be  use-
ful  for  reducing  the  duration  of  femoral  compression  and
allowing  rapid  patient  deambulation.
However,  in  the  speciﬁc  BAV  setting,  the  results  of
VCDs  have  been  poorly  evaluated.  Marchant  et  al.  reported
their  clinical  experience  of  successful  access  site  manage-
ment  with  the  pre-close  technique  after  aortic  valvuloplasty
in  four  patients  [11].  Solomon  et  al.  [12]  reviewed  31
consecutive  patients  who  underwent  percutaneous  aortic
valvuloplasty  and  suture  closure  with  the  Perclose  device
between  April  1998  and  September  2000.  Compared  with
39  consecutive  prior  patients  who  had  their  arterial  punc-
ture  managed  with  manual  compression,  stay  duration  was
shorter  (2.2  vs  5.3  days)  and  fewer  patients  received  blood
transfusions  (0%  vs  29%).  This  study  was  only  retrospective
and  vascular  complications  were  not  evaluated  precisely
[12].  Ben  Dor  et  al.  [25]  reported  results  of  a  cohort  study  of
333  patients  who  had  suture-based  and  collagen-based  VCDs
or  manual  compression  after  BAV,  using  10F  to  13F  sheaths;
they  observed  that  serious  vascular  complications  or  blood
transfusions  were  higher  in  the  manual  compression  group
(P  <  0.001).  Our  results  were  contradictory,  but  can  proba-
bly  be  explained  by  the  lower  size  of  the  sheaths  (8F  or  9F)
in  our  study  and  the  absence  of  the  use  of  heparin  during
the  procedure.  Therefore,  the  rate  of  bleeding  or  vascu-
lar  complications  with  manual  compression  in  our  study  was
less  than  half  of  that  observed  in  the  cohort  of  Ben  Dor  et  al.
(7.6%  vs  17%)  [25].
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Because  VCDs  remain  to  be  clinically  proven  and  have
dded  costs,  assessment  of  their  potential  advantages  and
dverse  events  in  a  population  of  elderly  patients,  who
ften  have  signiﬁcant  lower  extremity  atherosclerosis,  is  of
ajor  concern.  Our  prospective  study  involved  180  elderly
atients,  including  47  patients  (26%)  with  lower  limb  arte-
iopathy,  and  showed  an  increase  in  vascular  and  bleeding
omplications  in  general  (RR  2.60;  P  =  0.05),  associated
ith  a  signiﬁcant  increase  in  major  bleeding  complications
P  =  0.02)  when  using  these  devices.  These  results  were
bserved  without  the  use  of  heparin  during  the  procedure
nd  with  the  use  of  small-size  sheaths  (8F  or  9F).  Addition-
lly,  our  results  showed  a  trend  towards  increased  acute  limb
schaemia  with  VCDs,  which  can  be  a  serious  complication
hat  requires  urgent  surgical  management;  two  of  the  deaths
oncerned  these  types  of  patients.  Groin  infection  was  seen
n  three  patients,  all  in  group  1;  this  is  a  severe  event  that
eads  to  prolonged  hospital  stay  and  is  frequently  associated
ith  vascular  complications  [23].  Patients  with  lower  body
ass  index  (25  kg/m2; n  =  33)  tended  to  have  more  femoral
ccess  complications  (P  =  0.05),  but  did  not  take  advantage
f  VCDs  in  our  study  (P  =  0.5).  These  results  are  in  accordance
ith  those  of  Gurm  et  al.,  who  reported  that  the  beneﬁt  of
CDs  over  manual  closure  after  coronary  angioplasty  was
ttenuated  in  this  subgroup  [21].  Lastly,  the  devices  used  in
ur  study  did  not  reduce  the  duration  of  hospital  stay,  which
ccounts  for  a  signiﬁcant  part  of  the  hospital  cost,  probably
ecause  the  increased  rate  of  vascular  complications  affects
he  duration  of  hospitalization.
These  results  are  somewhat  different  from  those
bserved  with  coronary  diagnostic  or  therapeutic  interven-
ions,  where  VCDs  have  neutral  or  beneﬁcial  effects  on
leeding  complications,  and  may  often  reduce  the  dura-
ion  of  hospital  stay.  In  our  population  of  elderly  patients,
ho  probably  had  calciﬁed  and  atherosclerotic  arteries,  a
arge  (8F)  VCD  did  not  seem  to  be  beneﬁcial  and  could  even
e  harmful  in  some  cases.  While  the  majority  of  vascular
omplications  occurred  during  the  ﬁrst  day  after  deploy-
ent,  we  can  assume  that  the  femoral  arterial  wall  was
eakened  by  the  device  and  broke  a  few  hours  after  its
ntroduction.
Despite  the  potential  beneﬁt  of  VCDs  in  terms  of  early
mbulation  and  comfort  [17,18,22,26], our  results  argue
gainst  the  systematic  use  of  these  collagen  devices,  which
hould  be  limited  to  patients  at  high  risk  of  bleeding  with
anual  compression  (e.g.  requiring  anticoagulant  therapy).
hen,  the  American  Heart  Association  guidelines  recom-
end  such  therapy,  stating  that  VCDs  should  not  be  used
outinely  for  the  speciﬁc  purpose  of  reducing  vascular
omplications  in  patients  undergoing  invasive  cardiovascular
rocedures  via  the  femoral  artery  approach  (class  III,  level
f  evidence  C)  [27].
tudy limitations
he  non-randomized  nature  of  our  study  is  a  limitation,  as
t  can  lead  to  potential  bias  regarding  the  choice  of  whether
r  not  to  use  a  VCD.  Given  the  increased  use  of  BAV  as  a
ridge  to  TAVI  in  our  centre  since  2009,  operator  experience
ay  have  increased,  leading  to  a  reduction  in  the  rate  of
omplications  with  the  device.
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There  is  a  learning  curve  for  the  use  of  VCDs  [23],  and  it  is
ikely  that  better  patient  selection  and  improved  knowledge
f  the  device  result  in  lower  rates  of  vascular  complications.
owever,  the  three  interventional  cardiologists  had  several
ears  of  experience  with  the  device  before  beginning  the
tudy.
We  did  not  use  heparin  to  perform  valvuloplasty  in  our
tudy.  While  devices  are  usually  used  and  recommended
n  patients  at  high  risk  of  bleeding,  it  may  contribute  to
ncreasing  the  safety  of  manual  compression.
Even  if  collagen  haemostatic  devices  like  Angio-Seal  seem
o  be  the  most  secure  VCDs  [22,25],  these  results  can  not  be
xtended  to  other  devices,  such  as  Perclose  suture  devices.
Duration  of  hospital  stay  was  not  inﬂuenced  by  the
evice;  many  medical  or  social  factors  unrelated  to  vascular
omplications  may  inﬂuence  the  duration  of  hospital  stay  in
lderly  patients.
onclusions
ased  on  the  results  of  this  prospective  observational
tudy,  compared  with  manual  compression,  collagen  plug-
ased  VCDs  signiﬁcantly  increased  vascular  and  bleeding
omplications  occurring  after  BAV  performed  with  low  size
8F  and  9F)  sheaths  and  without  heparin  use.  Except  for
atients  at  high  risk  of  bleeding  with  manual  compres-
ion,  the  systematic  use  of  such  devices  in  a  population  of
lderly  patients  with  probable  advanced  limb  atherosclero-
is  is  questionable.
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